Table 2. Evaluation of resting and active VAS scores.

	PRP group			Placebo group			Total			p
	Mean±SD	Median	Min-Max	Mean±SD	Median	Min-Max	Mean±SD	Median	Min-Max
VAS during activity
Pre-treatment	7.61±1.72	8	5-10	8.00±1.86	8	5-10	7.77±1.76	8	5-10	0.512†
1-month post-treatment	6.38±2.26	6	2-1	6.00±3.09	7	0-10	6.22±2.59	6	0-10	0.851†
6-months post-treatment	5.46±2.18	5	2-10	4.70±2.95	4	0-10	5.13±2.51	5	0-10	0.363†
p value		0.030*‡			0.002**‡
Comparison
Pre-treatment vs. 1-month	-1.46±2.44			-1.80±2.04						0.679†
p value		0.239§			0.172§
Pre-treatment vs. 6-months	-2.38±2.79			-3.10±1.79						0.637†
p value		0.019*§			0.005**§
VAS at rest
Pre-treatment	4.44±2.36	5	0-8	4.58±2.61	4.5	0-9	4.50±2.42	5	0-9	0.983†
1-month post-treatment	3.77±2.59	5	0-8	3.40±3.24	4	0-9	3.61±2.82	4	0-9	0.636†
6-months post-treatment	3.31±3.43	2	0-9	1.60±1.90	1	0-5	2.57±2.94	2	0-9	0.269†
p value		0.226‡			0.025*‡
Comparison
Pre-treatment vs. 1-month	-1.08±2.78			-1.40±3.95						0.876†
p value		1.000§			1.000§
Pre-treatment vs. 6-months	-1.54±3.28			-3.20±3.29						0.224†
p value		0.350§			0.042*§
VAS: Visual Analog Scale; PRP: Platelet-rich plasma; SD: Standard deviation; † Mann Whitney U test; ‡ Friedman test; § Wilcoxon corrected pairwise comparison; * p<0.05; ** p<0.01.